Shopping Cart (0)
My Account

Your Shopping Cart
International Bioprinting CongressMetabomeeting 2014Drug Discovery India 2014Enabling Genomic Technologies and Screening Asia 2014Drug Metabolism & Discovery ADMET20% Discount OfferePoster Award PrizeBlogs

Cellular Therapy and Cord Blood 2013 Market Report

Publisher: Select Biosciences
Published: February 2013
Pages: 172 pages PowerPoint Main Report Plus Associated Data in Excel File

Price:



This is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences.

In this comprehensive market report, we have focused primarily on quantitative market metrics in order to characterize the growth and evolution of the cellular therapy field--in this vein, we present primary industry data that Select Biosciences has collected as part of its continual industry tracking of this space.

We've analyzed clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and present the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization.  We also present the breakout of clinical trials in the bona fide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated.

Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving.  Our coverage provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood.  Furthermore, given our global footprint, we've been able to compare the EU and US markets side-by-side in this analysis.

Select Biosciences also presents the ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union.  Details on the statute as well as implications to companies seeking to navigate this space are provided.

This Report is Written and Delivered to Customers in PowerPoint Format allowing convenient drag-and-drop for business plans, R&D presentations, investor presentations.  Report purchasers receive full commercial rights to use the data and analyses presented in the report for their in-house business activities.

Extensive Market Analyses Presented in this Report:

  • Regenerative Medicine and Stem Cell Research Activity in the US
  • Sales of Commercial Products and Services in Stem Cell/Regenerative Medicine Sectors
  • Breakout of Spending by Companies in the Cellular Therapy/Regenerative Medicine Space
  • Breakout of Spending by Product Platforms in Various Spaces
  • Autologous vs. Allogeneic Business Models in the Cellular Therapy Space
  • Autologous vs. Allogeneic Cellular Therapy: Industry SWOT
  • Adult Stem Cell Therapy Quantitative Market Forecast
  • Cellular Therapy Product Pipeline
  • Clinical Trials Quantitative Metrics and Detailed Breakout by Phase, Cell Type, Therapeutic Areas Addressed, Geography
  • HSCTs Performed in the EU: Percent Breakout by Disease Classes Addressed
  • Indications for HSCTs in North America: Disease Classes Addressed, Age of Recipients, Types of HSCs Utilized, Classes of Transplant Inoculum
  • Cost Analyses of HSCTs in the EU vs. US Markets
  • Cord Blood Banking Quantitative Market Metrics
  • Growth of BM, PBL, and CB Units Worldwide in Public Banks and Registries, Segmented by Country
  • Cord Blood Transplantation Trends: Age of Recipient, Disease Classes Addressed
  • EU and US Cord Blood Transplantation Detailed Cost Breakouts
  • EU ATMP Regulation Detailed Analysis
  • Stem Cells Worldwide Publications Analysis

Report Table of Contents (TOC) [Click Here to Download PDF File]

Sample Pages from the Market Report [Downloadable PDF File]


For enquiries about this market report, please contact Kathy Gray at Kathy.Gray@Selectbiosciences.com

Conference News
Papers presented in Drug Discovery India 2014 conference will be published in CRDD.
Papers presented in Drug Discovery India 2014 conference will be published in CRDD.
The Proceedings of Drug Discovery India 2014 conference will be published in a Special Issue of Current Research in Drug Discovery (CRDD) an online, free access, peer reviewed journal. To make the conference proceedings a timely publication, the authors are requested to submit the manuscripts prior to the start of the conference.


Submission Deadline Extended to the 15 August 2014
Submission Deadline Extended to the 15 August 2014
Submit your abstract for consideration to present at Lab-on-a-Chip Asia - Microfluidics and Point-of-Care Diagnostics.


Site Visit to the SIMTech Microfluidics Foundry
Site Visit to the SIMTech Microfluidics Foundry
Take advantage of a tour of the facilities at the SIMTech Microfluidic Foundry. Dr. Zhiping Wang, Director of Research Programmes, will be your host, providing all attendees with a detailed insight into the advanced work carried out by SIMTech. Don't miss out - Register today!


Papers Presented in Enabling Genomic Technologies & Screening Asia can be Published in CSBJ
Papers Presented in Enabling Genomic Technologies & Screening Asia can be Published in CSBJ
Computational and Structural Biotechnology Journal [CSBJ (ISSN 2001-0370)] will devote a conference special issue comprising of selected articles from the speakers/oral and poster presenters of Enabling Genomic Technologies & Screening Asia conference. Selected authors will receive an invitation to submit full length manuscripts to CSBJ. The full length manuscripts will undergo the peer-review process as per CSBJ policies. From July-2014, CSBJ will be part of ELSEVIER Open-access Journals.


The International Bioprinting Congress - Tour of facilities at the NTU Additive Manufacturing Centre
The International Bioprinting Congress - Tour of facilities at the NTU Additive Manufacturing Centre
An opportunity not to be missed. Take advantage of a free tour of the new NTU Additive Manufacturing Centre (NAMC). Supported by Singapore’s Economic Development Board (EDB), the NAMC will have the latest 3D printing machines, including bioprinters which are able to print human tissues. The centre opens officially in May 2014, so you will be one of the first to have an official guided tour with the Director of the Facility, Professor Chua Chee Kai.


ENABLING GENOMIC TECHNOLOGIES & SCREENING ASIA - EARLY BIRD
SAVE UP TO S$ 255 - EARLY BIRD DEADLINE 1 AUGUST 2014!

Scroll Up
Scroll Down
Keep me updated Select Bio Blog LinkedIn Twitter LabTube.tv SBOnDemand.com MarketReports.com Research-Store.com